Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03584165
Other study ID # 273CH201
Secondary ID 2017-003104-42
Status Enrolling by invitation
Phase Phase 3
First received
Last updated
Start date June 4, 2018
Est. completion date June 4, 2026

Study information

Verified date May 2023
Source Biogen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an antecedent study; these treated participants will be compared with untreated control participants who have exited the STAR (NCT03496012) study and BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been previously treated with BIIB112 and who have exited an antecedent study.


Description:

This study was previously posted by NightstaRx Ltd. In October 2020, sponsorship of the trial was transferred to Biogen.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 330
Est. completion date June 4, 2026
Est. primary completion date June 4, 2026
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Key Inclusion Criteria: CHM Participants a. Have participated in and exited from an interventional study that investigated the safety and efficacy of a sub-retinal injection of BIIB111 for CHM. XLRP Participants a. Have received a sub-retinal injection of BIIB112 for XLRP and have exited an antecedent study. Key Exclusion Criteria: Participants are not eligible for study participation if they meet the following exclusion criterion. a. In the opinion of the Investigator and/or the Sponsor, it is not in the participant's best interest to participate in the study. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design


Intervention

Genetic:
BIIB111
Administered as specified in the treatment arm.
BIIB112
Administered as specified in the treatment arm.

Locations

Country Name City State
Brazil Instituto Genetica Ocular Sao Paulo
Canada The Northern Alberta Clinical Trials and Research Centre Edmonton Alberta
Canada McGill University Health Centre Montreal Quebec
Canada The University of British Columbia - Eye Care Centre Vancouver British Columbia
Denmark Rigshospitalet-Glostrup, Oejenafdelingen Glostrup
Finland Helsinki University Central Hospital (HUCH) Helsinki
France CHU Montpellier - Saint Eloi Montpellier
France Centre Hospitalier National d Ophtalmologie (CHNO) des Quinze-Vingts Paris
Germany Universitäts-Augenklinik Bonn Bonn
Germany Universitats Klinikum Tubingen - Institute for Ophthalmic Research Tübingen
Netherlands Radboudumc Nijmegen
United Kingdom Moorfields Eye Hospital London
United Kingdom Manchester Royal Eye Hopsital Manchester
United Kingdom John Radcliffe Hospital Oxford
United Kingdom Southampton General Hospital Southampton
United States Johns Hopkins Hospital Baltimore Maryland
United States MEEI Massachusets Eye and Ear Infirmary Boston Massachusetts
United States Cincinnati Eye Institute - Blue Ash Cincinnati Ohio
United States Retina Foundation of the Southwest Dallas Texas
United States Vitreo Retinal Associates PA - The Millennium Center Gainesville Florida
United States UCLA - Jules Stein Eye Institute Los Angeles California
United States University of Wisconsin School of Medicine Madison Wisconsin
United States University of Miami Miami Florida
United States Columbia University Medical Center New York New York
United States OHSU - Casey Eye Institute Portland Oregon

Sponsors (1)

Lead Sponsor Collaborator
NightstaRx Ltd, a Biogen Company

Countries where clinical trial is conducted

United States,  Brazil,  Canada,  Denmark,  Finland,  France,  Germany,  Netherlands,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants with Adverse Events (AEs) Up to 5 years
Primary Ophthalmic Examination Assessment: Intraocular Pressure (IOP) Up to 5 years
Primary Ophthalmic Examination Assessment: Abnormal Slit Lamp Examination Up to 5 years
Primary Ophthalmic Examination Assessment: Lens Opacity Grading Up to 5 years
Primary Ophthalmic Examination Assessment: Anterior Chamber and Vitreous Inflammation Up to 5 years
Primary Ophthalmic Examination Assessment: Indirect Ophthalmoscopy Up to 5 years
Secondary Change from Baseline in Best-Corrected Visual Acuity (BCVA) BCVA will be assessed for both eyes using the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is to be reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Up to 5 years
Secondary Percentage of Participants with no Decrease from Baseline in BCVA or a Decrease from Baseline in BCVA of <5 ETDRS Letters in Choroideremia (CHM) Participants BCVA will be assessed for both eyes using the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is to be reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Up to 5 years
Secondary Percentage of Participants with an Increase from Baseline in BCVA of =10 ETDRS Letters in CHM Participants BCVA will be assessed for both eyes using the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is to be reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Up to 5 years
Secondary Percentage of Participants with an Increase from Baseline in BCVA of =15 ETDRS Letters in CHM Participants BCVA will be assessed for both eyes using the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is to be reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Up to 5 years
Secondary Assessment of Fundus Autofluorescence (AF) at Each Visit Fundus Autofluoroscence will be performed on both eyes to assess the change in the area of viable retinal tissue. It will be reported in square millimetres (mm^2). Up to 5 years
Secondary Assessment of Fundus Photography at Each Visit Fundus photography will be performed on both eyes following the dilation of the participant's pupils. Up to 5 years
Secondary Assessment of Spectral Domain Optical Coherence Tomography (SD-OCT) at Each Visit SD-OCT will be performed on both eyes to assess the foveal changes and other potential anatomic changes. The measurements were taken after dilation of the participant's pupil and would be reported in micrometres (µm). Up to 5 years
Secondary Assessment of Microperimetry at Each Visit Microperimetry will be performed on both eyes to assess changes in retinal sensitivity within the macula. It will be reported in decibels (dB). Up to 5 years
Secondary Change from Baseline in 25-Item Visual Function Questionnaire (VFQ-25) VFQ-25 questionnaire measures dimensions of self-reported vision-targeted health status that are most important to persons with eye disease. Total score ranges from 0-100, where a score of 0 represents the worst outcome and 100 represents the best outcome. Up to 5 years
Secondary Change from Baseline in Visual Field The outcome measure will be assessed in BIIB112-treated participants. Up to 5 years
Secondary Percentage of Participants with an Increase from Baseline in Luminance Visual Acuity (LLVA) of =10 ETDRS Letters in BIIB112-treated Participants The LLVA was measured by placing a 2.0-log-unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart. The assessment was performed prior to dilating the eyes. Initially, letters are read at a distance of 4 metres from the chart. If <20 letters are read at 4 metres, testing at 1 metre should be performed. BCVA is to be reported as number of letters read correctly by the participant. 18 Months to 60 Months, Post-Day 0 Visits
Secondary Percentage of Participants with an Increase from Baseline in Luminance Visual Acuity (LLVA) of =15 ETDRS Letters in BIIB112-treated Participants The LLVA was measured by placing a 2.0-log-unit neutral density filter over the best correction for that eye and having the participant read the normally illuminated ETDRS chart. The assessment was performed prior to dilating the eyes. Initially, letters are read at a distance of 4 metres from the chart. If <20 letters are read at 4 metres, testing at 1 metre should be performed. BCVA is to be reported as number of letters read correctly by the participant. 18 Months to 60 Months, Post-Day 0 Visits
See also
  Status Clinical Trial Phase
Completed NCT02553135 - Choroideremia Gene Therapy Clinical Trial Phase 2
Completed NCT01461213 - Gene Therapy for Blindness Caused by Choroideremia Phase 1/Phase 2
Completed NCT03507686 - A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 Phase 2
Recruiting NCT05258032 - Structural and Functional Characterization of Rare Ocular Diseases
Recruiting NCT05282953 - A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS) Phase 1/Phase 2
Withdrawn NCT05045703 - The Dark-Adapted Retinal Function Response in Choroideremia (DARC) Study N/A
Recruiting NCT01866371 - High Resolution Retinal Imaging
Completed NCT01603576 - Pilot Study of a Suprachoroidal Retinal Prosthesis N/A
Completed NCT03359551 - Natural History of the Progression of Choroideremia Study
Recruiting NCT02435940 - Inherited Retinal Degenerative Disease Registry
Active, not recruiting NCT04483440 - Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia Phase 1
Completed NCT02670980 - Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy N/A
Completed NCT02671539 - THOR - Tübingen Choroideremia Gene Therapy Trial Phase 2
Completed NCT02341807 - Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations Phase 1/Phase 2
Completed NCT03406416 - Study of a Suprachoroidal Retinal Prosthesis N/A
Enrolling by invitation NCT05158049 - Longitudinal Study of a Bionic Eye
Terminated NCT02994368 - "Natural History" Study of Choroideremia
Terminated NCT01654562 - The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia Phase 1/Phase 2
Active, not recruiting NCT00427180 - IRIS PILOT - Extended Pilot Study With a Retinal Implant System N/A
Completed NCT04750785 - A Study to Assess Choroideremia (CHM) Health Outcomes